Socinski M - Search Results

1

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis.

Langer CJ, Gajra A, Gridelli C, Konduri K, Morgensztern D, Spigel D, Talbot D, Thomas M, Weiss J, Pilot R, Bhore R, Wolfsteiner M, Ong TJ, Socinski M. Langer CJ, et al. Among authors: socinski m. Front Oncol. 2021 Jan 26;10:485587. doi: 10.3389/fonc.2020.485587. eCollection 2020. Front Oncol. 2021. PMID: 33575203 Free PMC article.

2

High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.

Socinski MA, Shea TC. Socinski MA, et al. Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-45-S12-51. Semin Oncol. 1997. PMID: 9331121 Review.

3

Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial.

Socinski MA, Clark JA, Halle J, Steagall A, Kaluzny B, Rosenman JG. Socinski MA, et al. Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-117-S12-122. Semin Oncol. 1997. PMID: 9331135 Clinical Trial.

4

The current status of adjuvant chemotherapy for resected non-small cell lung cancer.

Socinski MA. Socinski MA. Semin Oncol. 1999 Oct;26(5 Suppl 15):27-33. Semin Oncol. 1999. PMID: 10566608 Review.

5

Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer.

Socinski MA, Langer CJ. Socinski MA, et al. Semin Oncol. 1999 Oct;26(5 Suppl 16):51-61; discussion 71-2. Semin Oncol. 1999. PMID: 10585009 Review.

6

Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.

Socinski MA, Sandler AB, Miller LL, Locker PK, Hanover CK, Elfring GL, Israel VK, Pirotta N, Natale RB. Socinski MA, et al. J Clin Oncol. 2001 Feb 15;19(4):1078-87. doi: 10.1200/JCO.2001.19.4.1078. J Clin Oncol. 2001. PMID: 11181672 Clinical Trial.

7

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M, Kies MS. Socinski MA, et al. J Clin Oncol. 2002 Mar 1;20(5):1335-43. doi: 10.1200/JCO.2002.20.5.1335. J Clin Oncol. 2002. PMID: 11870177 Clinical Trial.

8

Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation.

Penland SK, Socinski MA. Penland SK, et al. Semin Radiat Oncol. 2004 Oct;14(4):326-34. doi: 10.1016/j.semradonc.2004.07.002. Semin Radiat Oncol. 2004. PMID: 15558508 Review.

9

Drug development in patients with advanced non-small cell lung cancer and poor performance status.

Stinchcombe TE, Socinski MA. Stinchcombe TE, et al. Semin Oncol. 2004 Dec;31(6 Suppl 11):21-6. doi: 10.1053/j.seminoncol.2004.10.005. Semin Oncol. 2004. PMID: 15599831 Review.

10

Pemetrexed (Alimta) in small cell lung cancer.

Socinski MA. Socinski MA. Semin Oncol. 2005 Apr;32(2 Suppl 2):S1-4. doi: 10.1053/j.seminoncol.2005.02.007. Semin Oncol. 2005. PMID: 15818532 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

344 results

Search Page

Filters